Advanced search
1 file | 845.74 KB

Vaccine-induced protection of Rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus

(2014) PLOS ONE. 9(11).
Author
Organization
Abstract
The mosquito-borne West Nile virus (WNV) causes human and animal disease with outbreaks in several parts of the world including North America, the Mediterranean countries, Central and East Europe, the Middle East, and Africa. Particularly in elderly people and individuals with an impaired immune system, infection with WNV can progress into a serious neuroinvasive disease. Currently, no treatment or vaccine is available to protect humans against infection or disease. The goal of this study was to develop a WNV-vaccine that is safe to use in these high-risk human target populations. We performed a vaccine efficacy study in non-human primates using the contemporary, pathogenic European WNV genotype 1a challenge strain, WNV-Ita09. Two vaccine strategies were evaluated in rhesus macaques (Macaca mulatta) using recombinant soluble WNV envelope (E) ectodomain adjuvanted with Matrix-M, either with or without DNA priming. The DNA priming immunization was performed with WNV-DermaVir nanoparticles. Both vaccination strategies successfully induced humoral and cellular immune responses that completely protected the macaques against the development of viremia. In addition, the vaccine was well tolerated by all animals. Overall, The WNV E protein adjuvanted with Matrix-M is a promising vaccine candidate for a non-infectious WNV vaccine for use in humans, including at-risk populations.
Keywords
ENCEPHALITIS-VIRUS, CYCLE FLAVIVIRUS VACCINE, CD8(+) T-CELLS, IMMUNE-RESPONSES, PRECLINICAL EVALUATION, ENVELOPE PROTEIN, UNITED-STATES, REPLIVAX WN, MICE, IMMUNOGENICITY

Downloads

  • Verstrepen et al. PlosOne 2014.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 845.74 KB

Citation

Please use this url to cite or link to this publication:

Chicago
Verstrepen, Babs E, Herman Oostermeijer, Zahra Fagrouch, Melanie van Heteren, Henk Niphuis, Tom Haaksma, Ivanela Kondova, et al. 2014. “Vaccine-induced Protection of Rhesus Macaques Against Plasma Viremia After Intradermal Infection with a European Lineage 1 Strain of West Nile Virus.” Plos One 9 (11).
APA
Verstrepen, B. E., Oostermeijer, H., Fagrouch, Z., van Heteren, M., Niphuis, H., Haaksma, T., Kondova, I., et al. (2014). Vaccine-induced protection of Rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLOS ONE, 9(11).
Vancouver
1.
Verstrepen BE, Oostermeijer H, Fagrouch Z, van Heteren M, Niphuis H, Haaksma T, et al. Vaccine-induced protection of Rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus. PLOS ONE. 2014;9(11).
MLA
Verstrepen, Babs E, Herman Oostermeijer, Zahra Fagrouch, et al. “Vaccine-induced Protection of Rhesus Macaques Against Plasma Viremia After Intradermal Infection with a European Lineage 1 Strain of West Nile Virus.” PLOS ONE 9.11 (2014): n. pag. Print.
@article{6839346,
  abstract     = {The mosquito-borne West Nile virus (WNV) causes human and animal disease with outbreaks in several parts of the world including North America, the Mediterranean countries, Central and East Europe, the Middle East, and Africa. Particularly in elderly people and individuals with an impaired immune system, infection with WNV can progress into a serious neuroinvasive disease. Currently, no treatment or vaccine is available to protect humans against infection or disease. The goal of this study was to develop a WNV-vaccine that is safe to use in these high-risk human target populations. We performed a vaccine efficacy study in non-human primates using the contemporary, pathogenic European WNV genotype 1a challenge strain, WNV-Ita09. Two vaccine strategies were evaluated in rhesus macaques (Macaca mulatta) using recombinant soluble WNV envelope (E) ectodomain adjuvanted with Matrix-M, either with or without DNA priming. The DNA priming immunization was performed with WNV-DermaVir nanoparticles. Both vaccination strategies successfully induced humoral and cellular immune responses that completely protected the macaques against the development of viremia. In addition, the vaccine was well tolerated by all animals. Overall, The WNV E protein adjuvanted with Matrix-M is a promising vaccine candidate for a non-infectious WNV vaccine for use in humans, including at-risk populations.},
  articleno    = {e112568},
  author       = {Verstrepen, Babs E and Oostermeijer, Herman and Fagrouch, Zahra and van Heteren, Melanie and Niphuis, Henk and Haaksma, Tom and Kondova, Ivanela and Bogers, Willy M and De Filette, Marina and Sanders, Niek and Stertman, Linda and Magnusson, Sofia and L{\"o}rincz, Orsolya and Lisziewicz, Julianna and Barzon, Luisa and Pal{\`u}, Giorgio and Diamond, Michael S and Chabierski, Stefan and Ulbert, Sebastian and Verschoor, Ernst J},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  language     = {eng},
  number       = {11},
  pages        = {10},
  title        = {Vaccine-induced protection of Rhesus macaques against plasma viremia after intradermal infection with a European lineage 1 strain of West Nile virus},
  url          = {http://dx.doi.org/10.1371/journal.pone.0112568},
  volume       = {9},
  year         = {2014},
}

Altmetric
View in Altmetric
Web of Science
Times cited: